Cynapsus Therapeutics Inc (CTH)

Toronto

Currency in CAD

53.50

0.00(0.00%)

Real-time Data·20/10

Day's Range

53.50

52 wk Range

0.00

53.50

CTH Financial Summary

A brief financial summary of Cynapsus Therapeutics Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-18.63

Price/Book8.72

Debt / Equity0%

Return on Equity-36.99%

Dividend Yield0.00%

EBITDA-40.11M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2006

31/12

2007

31/12

2008

31/12

2009

31/12

2010

31/12

2011

31/12

2012

31/12

2013

31/12

2014

31/12

2015

31/12

Total Revenues

Gross Profit

Operating Income

-2.19

-2.21

-4.59

-11.46

-40.28

Net Income

aa.aa

-2.85

-3.06

-4.43

-10.82

-27.47

Balance Sheet

Total Assets

aa.aa

1.2

1.17

3.15

18.55

106.87

Total Current Liabilities

aa.aa

4.04

6.18

2.56

3.08

5.24

Total Equity

aa.aa

-2.83

-5.01

0.59

15.47

101.63

Cash Flow

Levered Free Cash Flow

aa.aa

-1.17

-1.22

-1.78

-5.6

-15.23

Cash from Operations

aa.aa

-1.72

-1.34

-4.14

-9.99

-32.2

Cash from Investing

aa.aa

-0.04

-0.01

-0.26

-0.43

Cash from Financing

aa.aa

1.87

1.09

6.43

24.72

107.31

Net Change in Cash

aa.aa

0.1

-0.24

2.24

15.16

87.46

* In Millions of CAD (except for per share items)

Earnings

Latest Release

Aug 10, 2016

EPS / Forecast

-0.83 / -1.10

Revenue / Forecast

-- / 12.90K

EPS Revisions

Unlock

Last 90 days

NSE 30

5,152.99

+13.06

+0.25%

NSE All Share

141,439.75

+435.61

+0.31%

US 30

45,398.90

-232.8

-0.51%

US 500

6,464.70

-2.2

-0.03%

FTSE 100

9,321.40

+12.20

+0.13%

DAX

24,261.59

-101.50

-0.42%

South Africa Top 40

95,329.31

+262.45

+0.28%

Market Movers

Name	Last	Chg. %	Vol.
Fcmb	10.900	-0.91%	105.13M
Guaranty Trust Holding	96.05	+2.18%	25.00M
Access Holdings	27.45	+1.67%	15.69M
UBA	47.95	0.00%	14.23M
Zenith Bank	70.00	0.00%	10.18M
Aradel Holdings	510.00	-1.73%	2.66M
Julius Berger	146.10	+9.93%	2.15M

Name	Last	Chg. %	Vol.
Julius Berger	146.10	+9.93%	2.15M
Cutix	3.900	+9.86%	2.13M
Regal Insurance	1.47	+9.70%	15.85M
Veritas Kapital	2.17	+9.60%	59.57M
McNichols	3.50	+9.38%	677.72K
Nem	28.950	+8.83%	529.28K
Universal Insurance PLC	1.32	+8.20%	34.40M

Name	Last	Chg. %	Vol.
University Pre	5.540	-12.06%	681.46K
Cadbury Nig	57.85	-9.61%	660.41K
Abbey Mortgage Bank	6.55	-8.39%	254.88K
Daarcomm	1.12	-7.44%	3.04M
Austin Laz	2.71	-6.55%	2.59M
Mecure Industries	19.50	-6.02%	421.01K
Tantalizers	2.50	-5.66%	4.86M

Trending Stocks

Name	Last	Chg. %	Vol.
Mutual Benefits Assurance	4.45	+1.14%	18.05M
MTN Nigeria	435.00	0.00%	707.31K
Aiico	4.47	+6.94%	26.20M
Dangote Cement	520.00	0.00%	111.45K
Betaglas	449.35	0.00%	142.48K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaa A Aaaaa Aaaaaaaa	5,379.30	+46.90%	7,902.19
Aaaaaaa Aaa	520.00	+35.88%	706.58
A Aa Aaaaaaaaaaaaa	151.80	+31.85%	200.15
Aaa A Aaaa Aaaa A	1,890.00	+30.65%	2,469.28
Aaaaaaa	70.20	+18.13%	82.93
Aaa A	640.00	+17.25%	750.40

Name	Last	Upside	Fair Value
Aaa A Aaaaa Aaaaaaaa	5,379.30	+46.90%	7,902.19
Aaaaaaa Aaa	520.00	+35.88%	706.58
A Aa Aaaaaaaaaaaaa	151.80	+31.85%	200.15
Aaa A Aaaa Aaaa A	1,890.00	+30.65%	2,469.28
Aaaaaaa	70.20	+18.13%	82.93
Aaa A	640.00	+17.25%	750.40

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Cynapsus Therapeutics Inc (CTH)

CTH Financial Summary

Key Ratios

Statements Highlights

Earnings

Trending Stocks